Mankyu Park
Director/Board Member at Coagulant Therapeutics, Inc.
Mankyu Park active positions
| Companies | Position | Start | End |
|---|---|---|---|
Coagulant Therapeutics, Inc.
 Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Director/Board Member | - | - |
Career history of Mankyu Park
Former positions of Mankyu Park
| Companies | Position | Start | End |
|---|---|---|---|
| DTCP Management GmbH | Corporate Officer/Principal | - | - |
Training of Mankyu Park
| Goizueta Business School-Emory | Undergraduate Degree |
Statistics
International
| United States | 3 |
| South Korea | 2 |
Operational
| Director/Board Member | 1 |
| Corporate Officer/Principal | 1 |
| Undergraduate Degree | 1 |
Sectoral
| Health Technology | 2 |
| Finance | 2 |
| Consumer Services | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Private companies | 2 |
|---|---|
Coagulant Therapeutics, Inc.
Coagulant Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Coagulant Therapeutics, Inc. is a privately held company that focuses on designing, developing, and commercializing therapeutics for the coagulation cascade and its adjacencies. Coagulant Therapeutics is based in Berkeley, CA. The company's lead product candidate, CT-001, is a next-generation Factor VIIa designed for enhanced efficacy and safety in the setting of acute bleeding. The company is also developing additional therapeutics targeted to APC for the treatment of acute bleeding and other coagulation cascade-related diseases. The company was founded in 2019 by Terry Hermiston, who has been the CEO since then. | Health Technology |
| DTCP Management GmbH | Finance |
- Stock Market
- Insiders
- Mankyu Park
- Experience
